Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: GlobeNewswire
– Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML – – Mechanisms of Resistance and Relapse to Single Agent IDH1 Inhibitors Are Complex and Multiclonal and Include Both IDH-dependent and IDH-independent Pathways – – Company to Host Investor Event and Webcast Today at 8:00 p.m. ET – ORLANDO, Fla., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented translational data describing deep and durable molecular responses to treatment of TIBSOVO® (ivosidenib) and azacitidine and mechanisms of resistance and relapse to single agent treatment with TIBSOVO® in acute myeloid leukemia (AML) with an IDH1 mutation. The data were presented as part of the scientific program at the 2019 American Society of Hematology (ASH) Annual Meeting. “For 10 years, we have pioneered the science behi
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News [Yahoo! Finance]Yahoo! Finance
- Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and ExpositionGlobeNewswire
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
AGIO
Earnings
- 10/31/24 - Miss
AGIO
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 4
- 11/12/24 - Form 4
- AGIO's page on the SEC website